RGEN Repligen Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGEN
  4. Earnings
Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 65

EPS in 2026 (TTM): $0.75

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the EPS for the trailing twelve months is $0.75. Repligen's EPS for 2025 amounted to $0.87, marking an increase from -$0.46 in 2024. During the quarterly period ending on Jun 30, 2026, RGEN's EPS stood at $0.09.

RGEN earnings history

Historical annual and quarterly earnings per share (EPS) data for Repligen
EPS (TTM)
$0.75
EPS Growth YoY (Quarterly)
-65.4%
EPS (Quarterly)
$0.09
EPS Growth (Quarterly)
-40%

Repligen had an annual EPS of $0.87, indicating an increase of 289.1% from -$0.46 in 2024. The quarterly per-share earnings for the period ending Jun 30, 2026, was $0.09, indicating a 65.4% decrease from the same quarter last year. RGEN's 12-month EPS stands at $0.75 as of June 2026. Repligen's annual EPS in 2024 stood at -$0.46, a 171.9% decrease year-over-year.

RGEN earnings chart

RGEN EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-65.4%
EPS growth YoY
289.1%
EPS growth 3Y avg
-36.2%
EPS growth 5Y avg
-5.3%

Repligen has registered a decrease in EPS of 65.4% during the last 12 months (YoY, quarterly). In the last three years, RGEN recorded an average annual EPS growth rate of -36.2%. Repligen had an average annual EPS growth rate of -5.3% during the last 5 years. Across the last decade, RGEN had an average annual EPS growth of 12%.

RGEN Earnings Waterfall

Breakdown of revenue, profit and net income for Repligen

RGEN Earnings vs Peers

What are the earnings of RGEN compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 14.35 178.7% 5.3% N/A
PFE Pfizer Inc 19.03 -3.5% -37.4% -3.7%
NBIX Neurocrine Biosciences Inc 23.91 41.5% 44% 1.9%
TMO Thermo Fisher Scientific Inc 30.89 7.2% 0% 2%
GE General Electric Company 42.57 35.8% 447.4% 12.1%
BMRN Biomarin Pharmaceutical Inc 42.83 -19.1% 33.8% -17.4%
TECH Bio-Techne Corp 101.62 -56.1% -35.2% -20.7%
RGEN Repligen Corp 194.67 289.1% -36.2% -5.3%
NVAX Novavax Inc N/A 321.1% N/A N/A
CRL Charles River Laboratories International Inc N/A -1,555% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.